- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead ; volume:24 ; number:5 ; day:25 ; month:3 ; year:2023 ; pages:442-465 ; date:5.2023
Current treatment options in oncology ; 24, Heft 5 (25.3.2023), 442-465, 5.2023
- Creator
-
Grinda, Thomas
Rassy, Elie
Pistilli, Barbara
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-023-01072-5
- URN
-
urn:nbn:de:101:1-2023090209164238137292
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Grinda, Thomas
- Rassy, Elie
- Pistilli, Barbara
- SpringerLink (Online service)
Other Objects (12)
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–drug conjugates in ovarian cancer
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–drug conjugates in ovarian cancer
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates